Scope: Birth cohorts typically measure plasma folate in midgestation, but effects of folic acid supplementation are sometimes specific to the periconceptional period. The relationship between midgestation plasma folate and periconceptional supplementation is not known. We compared plasma folate at week 18 of gestation with self-report use of supplements comtaining folic acid from before pregnancy to week 17 of gestation.
Introduction
Folate is involved in cell division, cell differentiation, nucleotide synthesis, and DNA methylation and is important for fetal development [1, 2] . Maternal use of folic acid supplements has been shown to reduce the risk of having a child with neural tube defects [3] [4] [5] [6] [7] [8] [9] . For the protective effect to occur, the folic acid supplement must be taken before the neural tube closure around day 28. The official guideline in Norway is to take a folic acid supplement of 400 g a day, to start a month before conceiving, and to use the supplement through the second or third month of pregnancy [10, 11] . Norway has not implemented any policy of food supplementation with folate.
With data from the Norwegian Mother and Child Cohort Study (MoBa), we recently showed that maternal use of folic acid taken before 8 wk of gestation was related to reduced risk of the child having severe language delay at the age of 3 [12] . Folic acid supplementation after week 8, however, was not related to language delay in the child at the age of 3. This suggests that the relation of folic acid intake to severe language delay could also be gestation specific.
It would have been useful to also have plasma folate levels for the period before 8 wk of gestation. Supplementation intake may be imperfectly recalled and reported [13] . In MoBa, however, the earliest time at which plasma folate could be measured was in the samples taken around week 18 (17-wkcompleted gestation) . This is similar to other large prospective pregnancy cohorts; the first blood sample is often collected in the second trimester [14] [15] [16] .
Nonetheless, available data from MoBa offer a unique opportunity to shed light on the validity of self-report data, and examine the utility of week 18 plasma folate as an indicator of supplementation in the periconceptional period. Plasma folate at week 18 has been measured for a randomly selected subsample of participating women in MoBa, and MoBa collects remarkably detailed self-report data about maternal supplement use from before pregnancy to 17 wk of gestation. Thus, we could assess the strength and coherence of the relationship between self-reported folate supplementation and plasma folate at week 18. We could also examine the relation of maternal plasma folate at week 18 to self-reported periconceptional supplementation. We focused on supplementation use before week 8 of gestation, the interval implicated in our previous study of language delay [12] .
Materials and methods

Study population
This study is based on MoBa, which is a prospective pregnancy cohort that has been described in detail elsewhere [17] . 108 841 pregnant women enrolled in the study during the recruitment period between 1999 and 2008, with a participation rate of 38.5% (http://www.fhi.no/moba-en). Written informed consent was obtained from each participant and the study was approved by the Regional Committee for Medical Research and the Norwegian Data Inspectorate.
The present analysis used a substudy of 3045 women in MoBa that has also been described in detail elsewhere [18] . Briefly, these women were a random sample of pregnant women enrolled in MoBa who gave birth during the period July 2002-December 2003, donated blood around week 18, returned the first pregnancy questionnaire and a Food Frequency Questionnaire, and were registered in the Medical Birth Registry of Norway. Since concurrent intake of antibiotics may interfere with microbiological assays and falsely reduce plasma levels of folate to extremely low levels [19] , we excluded samples with plasma folate levels less than 2.33 nmol/L (n = 30, i.e. the lower one percentile). We also excluded 106 samples from pregnancies that led to twins or triplets. The remaining 2911 pregnancies were used in this analysis.
Variables
Information on dietary supplement use was collected using the first pregnancy questionnaire. Women received this questionnaire, after they had signed up for a routine ultrasound examination offered freely to all pregnant women in weeks 17-18 of pregnancy. It included detailed questions about use of vitamins, minerals, and other dietary supplements in 4-wk time windows from before pregnancy. They were asked to record the use according to the ingredient list on the supplement container. Self-reported use of folic acid and other dietary supplements has been described previously in this cohort [18, 20, 21] .
For the present analysis, we created six variables to examine timing of folic acid supplementation: (i) supplementation in weeks 13-17; (ii) supplementation in weeks 9-12; (iii) supplementation in weeks −4-8; (iv) initiation of supplementation: no folic acid; weeks −4-0; 0-4; 5-8; 9-12; 13-17); (v) supplementation in every 4-wk period from −4 to 17; (6) supplementation in every 4-wk period from −4 to 12. For the first three of these six variables, we differentiated supplement use into four mutually exclusive categories: (i) no use of dietary supplements; (ii) other supplements, but no folic acid; (iii) folic acid only; (iv) folic acid in combination with other supplements. For the other three of these six variables, we combined (i) and (ii) to represent "no folic acid supplementation," and combined (iii) and (iv) to represent "folic acid supplementation."
As shown in Table 1 , potential confounders were maternal education (<12 years; 12 years, 13-16 years, 17+ years); maternal age (<25 years, 25-29 years, 30-34 years, 35+ years); planned pregnancy (no/yes); parity (0, 1, 2+); BMI (<25, 25-29, 30-34, 35+); smoking (no, sometimes, daily). Plasma folate values are presented as medians and interquartile ranges.
Laboratory measurements
Collection of biological samples and laboratory methods have been described previously [22] . Nonfasting blood samples were used for the preparation of plasma, collected into EDTA tubes, centrifuged within 30 min after collection, and placed in the hospital refrigerator (4ЊC). They were sent by ordinary postal service over-night to the Biobank of MoBa at the Norwegian Institute of Public Health. On the day of receipt (usually 1-2 days after blood collection), EDTA plasma samples were aliquoted onto polypropylene microtiter plates (300 L in each well, 96-well format), sealed with heat-sealing foil sheets, and stored in a freezer at −80ЊC. Plasma folate was determined by microbiological assay, using a chloramphenicol resistant strain of Lactobacillus casei [23] . The assay determines biologically active folate species, predominantly 5-methyl-tetrahydrofolate, and has a CV that corresponds to 4% within-day and 5% between days, at a population median. The sample handling did not involve addition of ascorbic acid.
Statistical analysis
To compute p values for differences in plasma folate medians, we used the Kruskal-Wallis test. To describe the relationship between supplement use (no supplements; other supplements; folic acid only; folic acid plus) in the three windows of exposure (weeks 13-17; 9-12; −4-8) we used Spearman's rank correlation. To examine the relationship of self-reported supplement use within three specified time periods (weeks 13-17; 9-12; −4-8) to plasma folate at week 18, we used unadjusted and adjusted linear regression models with plasma folate as a continuous outcome. The predictor variables were dummy variables created from the four categories of supplement use (no supplement; other supplement; folic acid only; folic acid plus) within each of these three time periods of exposure. The nonstandardized regression coefficient (B) shows the expected difference in nanomole per liter plasma folate for the different exposure categories (type of supplement used) with no supplement use as the reference category. We further examined the relationship of folic acid use according to when folic acid was started (weeks −4-0; 0-4; 5-8; 9-12; 13-17) to plasma folate at week 18. Predictor variables were dummy variables created for folic acid use (no/yes) within each of the 4-wk windows, with no folic acid use as the reference category. We also examined the relationship of continuous folic acid use (from weeks −4 to 17) to plasma folate at week 18. Since some women used folic acid before conception but 
Results
The mean age of the pregnant women was 30 years, more than 40% had 13-16 years of education, more than 40% were pregnant with their first child, 77% said the pregnancy was planned, 65% had a BMI less than 25 kg/m 2 , and about 12% reported smoking (Table 1) .
The relationship between maternal report of supplement use and maternal plasma folate, respectively, with covariates (maternal age, BMI, education, pregnancy planning, parity, and smoking) are presented in Table 1 . All the covariates showed some association with either supplement use or plasma levels, or both. Table 2 describes the patterns of reported folate supplementation for three time periods (weeks 13-17; 9-12; −4-8). The use of "folic acid only" was higher (17-18%) for weeks −4-8 and weeks 9-12 than for weeks 13-17 (7.2%). Cessation of folic acid supplements after week 12 would be in accord with official Norwegian guidelines. By contrast, use of "folic acid in combination with other supplements" was similar (32%) in all three periods.
Correlations between the three periods (weeks 13-17; 9-12; −4-8) of supplement use (no supplements; other supplements; folic acid only; folic acid plus) are presented in Table 3 and ranged from 0.39 to 0.66 (all significant at p < 0.001). Table 4 ). Women that reported continuous use through week 17 had about threefold higher median plasma folate than women reporting no folic acid use at all in the same period. Table 5 presents the relation between plasma folate and patterns of reported supplement use in three models, based on linear regression, for three different periods, with "no supplement use" as the reference in each. Model 1 is unadjusted; model 2 adjusted for all the covariates in Table 1 ; and model 3 is further adjusted by including the use of supplements in the other two periods. The nonstandardized regression coefficient (B) shows the expected difference in nanomole per liter plasma folate for the different exposure categories (type of supplement used). In model 3, reported use of folic acid only and folic acid plus in weeks 13-17 shows a strong relationship with plasma folate levels in week 18. The same relationship is not evident for report of use in weeks 9-12 and weeks −4-8. This lack of association would be expected for two reasons related to the change in pattern of supplement use. First, 50% of women report to use folic acid in weeks 9-12, while in weeks 13-17 the proportion of use is down to 40% (Table  2) . Those women who discontinue the use after week 12 are mainly the women that used folic acid only. Second, as can be seen under (4) in Table 4 several women, that reported no use of folic acid in weeks −4-8, started to use folic acid in weeks 9-17.
When analyzing the relationship according to start of folic acid use and plasma folate levels, weeks 13-17 again showed the strongest association. Continuous use of folic acid from weeks −4 to 17 showed a stronger association than continuous use that was discontinued by week 12 (Table 6 ).
Discussion
There were three main findings. First, we found intriguing differences in the patterns of use among those who reported using folic acid only, and those using folic acid in combination with other supplements. About 18% of the women used "folic acid only" in the period from before pregnancy to 12 wk of gestation, but after week 12, about 60% of these stopped taking folic acid. They were most likely following the official Norwegian guidelines, i.e. they used a folic acid supplement of 400 g and stopped after the third month of pregnancy. For those women who reported folic acid use in combination with other supplements, the proportion did not change; about 32% took supplements in all three windows of exposure. This group probably contains women who only used a multivitamin, as well as those who used other vitamins or supplements with various amounts of folic acid. Supplement use patterns are included as dummies. Linear regression was used to determine the coefficients for folate plasma levels (subjects with no supplement use in the relevant period as reference, B = 0). Missing was excluded pairwise. a) Adjusted for education, age, planned pregnancy, BMI, and smoking. b) Adjusted for education, age, planned pregnancy, BMI, smoking, and the other windows of supplement use (weeks 9-12 and -4-8; 13-17 and -4-8; 13-17 and 9-12). Folic acid use dichotomized. Linear regression was used to determine the coefficients for folate plasma levels (subjects with no folic acid supplement use as reference, B = 0). a) Adjusted for education, age, planned pregnancy, BMI, and smoking.
Second, maternal report of timing and length of folic acid supplements was well reflected in maternal folate plasma levels in week 18. Plasma folate levels in week 18 were most strongly associated with the maternal report of folic acid use in weeks [13] [14] [15] [16] [17] . Women who reported the use of folic acid in this period had higher plasma folate than women with no use of folic acid in the same period, regardless of whether a folic acid supplement had been used earlier in pregnancy. A small group of women reported continuous use of folic acid supplements from before pregnancy to week 17. These women had the highest plasma folate levels, likely reflecting that plasma folate is a function of accumulative folate intake. We did, however, observe that women who followed the official guidelines, to use folic acid from before pregnancy through the second or third month of pregnancy (but not after week 12), had lower plasma folate levels than women who reported folic acid use in weeks 13-17 only.
Third, we found no association between plasma folate levels in week 18 and maternal report of folic acid use during the period from before pregnancy to 8 wk of gestation, absent continued use continued use of folate after week 8. We suggest two main reasons for this finding. One is that, as noted above, some women took folic acid supplements in accord with official Norwegian guidelines, i.e. stopped taking folic acid supplements at week 12. The lower levels in this group may reflect the natural progression of pregnancy (increasing plasma volume and increasing utilization of available folate), which could lead to depleted folate levels between folic acid discontinuation (week 12) and blood sampling (week 18) [24, 25] . The other is that some of the women, who did not take folic acid supplements during the period before pregnancy to 8 wk of gestation, started taking folic acid after week 8. This would increase their plasma folate levels at week 18, especially because of the strong influence of recent intake.
To our knowledge, this is the first prospective study where pregnant women responded to detailed questions regarding supplement use over 4-wk periods, referring to ingredients lists on the supplement containers. The precision of these data made it possible to differentiate patterns of maternal report of supplement use with plasma folate levels in week 18 (also the median week for return of the questionnaire). The detailed data collection also made it possible to create four mutually exclusive categories of supplement use, and thereby separate women who used folic acid only from women who used folic acid together with other micronutrients. Strengths of our study include its prospective design, detailed assessment of supplement use, careful measurement of plasma folate in week 18, and detailed information about important covariates.
A potential weakness is that recall may be better for more recent supplement use. Another limitation is that we had no information on the dose of folic acid taken. We also acknowledge that the use of nonfasting plasma samples might have added preanalytical variation, potentially attenuating the associations. It should be noted that the optimal folic acid dose has not been established. Official guidelines for periconceptional supplement use and food fortification with folate, vary among countries. For example, the official guideline in the US recommends a higher daily intake (400-800 g) [26] , although the recommended time period for use is similar to Norway (from 1 month before conception through the first trimester). Also, by contrast with Norway, the US has a policy of food supplementation with folate. These and other differences (e.g. dietary patterns) need to be taken into account when considering the implications of these findings for studies in other countries. Finally, while this paper has focused primarily on periconceptional use of folic acid, it should be kept in mind that the use of folic acid may be beneficial throughout pregnancy and lactation. For example, folic acid use later in pregnancy has been associated in some studies with reduced risk of preterm birth and low-birth babies [27, 28] . In a previous publication from the MoBa cohort, however, we did not find maternal folate status in the second trimester to be associated with either birth weight or gestational age [18] .
In conclusion, our results suggest that self-reported folic acid use had a strong and coherent relationship with plasma folate at week 18. But self-reported use from before pregnancy to 8 wk of gestation was not associated with plasma folate at week 18, absent continued use after week 8. For periconceptional supplementation per se, self-report may offer a better measure than plasma folate at week 18. 
